SVCM
MNPR icon

Saturn V Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Saturn V Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.9M Sell
311,976
-33,650
-10% -$2.08M 4.14% 12
2026
Q1 		$18.9M Buy
345,626
+19,925
+6% +$1.2M 3.43% 12
2025
Q4 		$21.3M Buy
325,701
+170,331
+110% +$13.9M 3.9% 12
2025
Q3 		$12.7M Buy
+155,370
New +$6.95M 2.78% 16

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Saturn V Capital Management's MNPR Position: Q2 2026 in Review

Saturn V Capital Management reduced its Monopar Therapeutics (MNPR) stake by 9.7% in Q2 2026, selling an estimated $2.08M and leaving 311,976 shares worth $28.9M. The position accounts for 4.14% of the portfolio, ranked #12.

Saturn V Capital Management first reported a position in MNPR in Q3 2025 and has held it in 4 quarters since. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Saturn V Capital Management held 311,976 shares of Monopar Therapeutics worth $28.9M as of Q2 2026.
  • Saturn V Capital Management sold 33,650 Monopar Therapeutics shares in Q2 2026, an estimated $2.08M.
  • Monopar Therapeutics made up 4.14% of Saturn V Capital Management's portfolio in Q2 2026, its #12 holding.
  • Saturn V Capital Management first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.